Saama Analytics

Saama Analytics, founded in 1997 by Suresh Katta, is a California-based company specializing in AI-driven data analytics and clinical research solutions.

Reviewed by 7wData
Share Email

On this page

Profile

Saama Analytics provides AI-driven data analytics solutions to streamline clinical trials and enhance data-driven decision-making in the life sciences sector.

Saama Analytics, founded in 1997 by Suresh Katta, is a California-based company specializing in AI-driven data analytics and clinical research solutions. The company has positioned itself as a key player in the life sciences sector, offering tools that streamline clinical trial processes and enhance data-driven decision-making. Saama raised $70 million in a Series C funding round in November 2021, led by Sorenson Capital, to expand its AI platform for training data.

The company has a global presence, with offices in the US, Europe, and Asia, and serves a diverse clientele, including pharmaceutical companies, biotech firms, and contract research organizations (CROs). Saama's flagship product, the Clinical Data Cloud, integrates AI and machine learning to accelerate clinical trial data processing and analysis. The company has been recognized for its innovative approach, winning awards such as the Frost & Sullivan Best Practices Award in 2020. Despite its successes, Saama faces challenges in maintaining its competitive edge in a rapidly evolving AI landscape and addressing concerns over data privacy and security.

Track Saama Analytics and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Pharmaceutical companies
  • Biotech firms
  • Contract research organizations (CROs)
  • Academic research institutions
  • Healthcare providers

Strengths and what to watch

Strengths

  • Strong focus on AI-driven solutions for clinical trials
  • Global presence with offices in the US, Europe, and Asia
  • Recognition and awards for innovation in data analytics

Watch for

  • Competition from emerging AI startups in the life sciences sector
  • Data privacy and security concerns
  • Dependence on funding rounds for expansion and innovation

Key Information

Founded
1997

Frequently Asked Questions

What does Saama Analytics do?

Saama Analytics provides AI-driven data analytics solutions for clinical trials, helping pharmaceutical companies and research organizations streamline processes and improve decision-making. Their flagship Clinical Data Cloud integrates machine learning to accelerate trial data analysis. Founded in 1997, they serve global clients across life sciences.

Who uses Saama Analytics' services?

Saama primarily serves pharmaceutical companies, biotech firms, and contract research organizations (CROs). Their AI analytics platform also supports academic research institutions and healthcare providers needing advanced clinical trial data processing. The company operates globally with offices in the US, Europe, and Asia.

How much funding has Saama Analytics raised?

In November 2021, Saama secured $70 million in Series C funding led by Sorenson Capital. This investment supports expansion of their AI platform for clinical trial data training. The company has maintained steady growth since its 1997 founding.

What makes Saama Analytics different from other clinical trial AI providers?

Saama's Clinical Data Cloud combines AI and machine learning specifically for life sciences applications. Their focus on end-to-end clinical trial solutions and Frost & Sullivan award recognition distinguish them from generic analytics providers. However, they face competition from specialized AI startups.

What awards has Saama Analytics won?

Saama received the Frost & Sullivan Best Practices Award in 2020 for innovation in data analytics. This recognition highlights their AI-driven approach to accelerating clinical research while maintaining data integrity across global pharmaceutical and biotech partnerships.

What challenges does Saama Analytics face?

Saama must maintain technological leadership against emerging AI startups while addressing data privacy concerns. Their growth depends on continued funding rounds and adapting to evolving regulatory requirements in global clinical research markets. The competitive life sciences analytics sector demands constant innovation.

Sources

  1. techcrunch.com — Series C funding round led by Sorenson Capital
  2. www.reuters.com — Suresh Katta's nomination to Novavax's board
  3. saamaanalytics.com — Overview of Saama's products and services
  4. www.crunchbase.com — General company information and funding details